{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:43:32Z","timestamp":1771461812103,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Aarhus University"},{"DOI":"10.13039\/100007405","name":"Danish Heart Foundation","doi-asserted-by":"crossref","award":["11-04-R84-A3234-22641"],"award-info":[{"award-number":["11-04-R84-A3234-22641"]}],"id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"crossref","award":["11\u2013107461"],"award-info":[{"award-number":["11\u2013107461"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010078","name":"Central Denmark Region","doi-asserted-by":"crossref","award":["1-45-72-4-09"],"award-info":[{"award-number":["1-45-72-4-09"]}],"id":[{"id":"10.13039\/501100010078","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eva and Henry Fr\u00e6nkels Foundation"},{"name":"Fabrikant Karl G. Andersens Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s00392-019-01553-4","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T22:07:05Z","timestamp":1569535625000},"page":"638-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Optimizing heart failure treatment following cardiac resynchronization therapy"],"prefix":"10.1007","volume":"109","author":[{"given":"Anders","family":"Jorsal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0182-8718","authenticated-orcid":false,"given":"Kasper","family":"Pryds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Wiggers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Cosedis","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roni Rangh\u00f8j","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"issue":"5","key":"1553_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325(5):293\u2013302","journal-title":"N Engl J Med"},{"key":"1553_CR2","unstructured":"MERIT-HF Study Group (1999) Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353(9169):2001\u20132007"},{"issue":"10","key":"1553_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717","journal-title":"N Engl J Med"},{"issue":"15","key":"1553_CR4","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1056\/NEJMoa050496","volume":"352","author":"JG Cleland","year":"2005","unstructured":"Cleland JG, Daubert JC, Erdmann E et al (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352(15):1539\u20131549","journal-title":"N Engl J Med"},{"issue":"14","key":"1553_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","volume":"361","author":"AJ Moss","year":"2009","unstructured":"Moss AJ, Hall WJ, Cannom DS et al (2009) Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361(14):1329\u20131338","journal-title":"N Engl J Med"},{"issue":"12","key":"1553_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa013474","volume":"346","author":"AJ Moss","year":"2002","unstructured":"Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12):877\u2013883","journal-title":"N Engl J Med"},{"issue":"23","key":"1553_CR7","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","volume":"133","author":"N Okumura","year":"2016","unstructured":"Okumura N, Jhund PS, Gong J et al (2016) Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Circulation 133(23):2254\u20132262","journal-title":"Circulation"},{"issue":"1","key":"1553_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJ, Desai AS et al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131(1):54\u201361","journal-title":"Circulation"},{"issue":"8","key":"1553_CR9","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18(8):891\u2013975","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"1553_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS et al (2014) Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993\u20131004","journal-title":"N Engl J Med"},{"issue":"9744","key":"1553_CR11","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Bohm M et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875\u2013885","journal-title":"Lancet"},{"key":"1553_CR12","doi-asserted-by":"crossref","unstructured":"Martens P, Nuyens D, Rivero-Ayerza M et al (2019) Sacubitril\/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol 108(10):1074\u20131082","DOI":"10.1007\/s00392-019-01440-y"},{"issue":"14","key":"1553_CR13","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787\u20131847","journal-title":"Eur Heart J"},{"key":"1553_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1745-6215-14-113","volume":"14","author":"A Sommer","year":"2013","unstructured":"Sommer A, Kronborg MB, Poulsen SH et al (2013) Empiric versus imaging guided left ventricular lead placement in cardiac resynchronization therapy (ImagingCRT): study protocol for a randomized controlled trial. Trials 14:113","journal-title":"Trials"},{"issue":"9","key":"1553_CR15","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"JJ McMurray","year":"2013","unstructured":"McMurray JJ, Packer M, Desai AS et al (2013) Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 15(9):1062\u20131073","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"1553_CR16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/ejhf.530","volume":"18","author":"A Sommer","year":"2016","unstructured":"Sommer A, Kronborg MB, Norgaard BL et al (2016) Multimodality imaging-guided left ventricular lead placement in cardiac resynchronization therapy: a randomized controlled trial. Eur J Heart Fail 18(11):1365\u20131374","journal-title":"Eur J Heart Fail"},{"issue":"27","key":"1553_CR17","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"issue":"3","key":"1553_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1136\/heart.87.3.235","volume":"87","author":"J Juenger","year":"2002","unstructured":"Juenger J, Schellberg D, Kraemer S et al (2002) Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87(3):235\u2013241","journal-title":"Heart"},{"issue":"5","key":"1553_CR19","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1161\/01.CIR.0000136991.85540.A9","volume":"110","author":"GE Soto","year":"2004","unstructured":"Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA (2004) Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation 110(5):546\u2013551","journal-title":"Circulation"},{"issue":"19","key":"1553_CR20","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/eurheartj\/ehr343","volume":"32","author":"I Ekman","year":"2011","unstructured":"Ekman I, Chassany O, Komajda M et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32(19):2395\u20132404","journal-title":"Eur Heart J"},{"issue":"8","key":"1553_CR21","doi-asserted-by":"publisher","first-page":"e003430","DOI":"10.1161\/CIRCHEARTFAILURE.116.003430","volume":"10","author":"EF Lewis","year":"2017","unstructured":"Lewis EF, Claggett BL, McMurray JJV et al (2017) Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail 10(8):e003430","journal-title":"Circ Heart Fail"},{"issue":"21","key":"1553_CR22","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa032423","volume":"350","author":"MR Bristow","year":"2004","unstructured":"Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350(21):2140\u20132150","journal-title":"N Engl J Med"},{"issue":"19","key":"1553_CR23","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.jacc.2012.06.054","volume":"60","author":"PJ Veazie","year":"2012","unstructured":"Veazie PJ, Noyes K, Li Q et al (2012) Cardiac resynchronization and quality of life in patients with minimally symptomatic heart failure. J Am Coll Cardiol 60(19):1940\u20131944","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1553_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cardfail.2017.03.001","volume":"23","author":"P Martens","year":"2017","unstructured":"Martens P, Verbrugge FH, Nijst P et al (2017) Feasibility and association of neurohumoral blocker up-titration after cardiac resynchronization therapy. J Card Fail 23(8):597\u2013605","journal-title":"J Card Fail"},{"issue":"16","key":"1553_CR25","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/eurheartj\/eht514","volume":"35","author":"S Schmidt","year":"2014","unstructured":"Schmidt S, Hurlimann D, Starck CT et al (2014) Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Eur Heart J 35(16):1051\u20131060","journal-title":"Eur Heart J"},{"issue":"3","key":"1553_CR26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/ehjcvp\/pvv016","volume":"1","author":"CT Witt","year":"2015","unstructured":"Witt CT, Kronborg MB, Nohr EA, Mortensen PT, Gerdes C, Nielsen JC (2015) Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival. Eur Heart J Cardiovasc Pharmacother 1(3):182\u2013188","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"1553_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/europace\/euy267","volume":"21","author":"F Leyva","year":"2018","unstructured":"Leyva F, Zegard A, Okafor O et al (2018) Survival after cardiac resynchronization therapy: results from 50 084 implantations. Europace 21(5):754\u2013762","journal-title":"Europace"},{"key":"1553_CR28","doi-asserted-by":"publisher","unstructured":"Hamed S, Schmack B, Mueller F et al (2019) Implementation of an intensified outpatient follow-up protocol improves outcomes in patients with ventricular assist devices. Clin Res Cardiol. \nhttps:\/\/doi.org\/10.1007\/s00392-019-01451-9","DOI":"10.1007\/s00392-019-01451-9"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01553-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T23:52:32Z","timestamp":1600991552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01553-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01553-4","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor John J. V. McMurray\u2019s employer, Glasgow University, has been paid by Novartis for his time spent as Principal Investigator\/Executive\/Steering Committee member for a number of clinical trials using sacubitril\/valsartan and meetings and lectures related to sacubitril\/valsartan. The Novo Nordisk Foundation (NNF16OC0018658) financially supports Professor Jens Cosedis Nielsen. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Raw data and statistical coding are available from the corresponding author at kpryds@clin.au.dk","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}]}}